Supernus Pharmaceuticals Stock Math Operators Price Series Summation
| SUPN Stock | USD 53.22 -0.45 -0.84% |
| Symbols |
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Supernus Pharmaceuticals Price Series Summation is a cross summation of Supernus Pharmaceuticals price series and its benchmark/peer.
Supernus Pharmaceuticals Technical Analysis Modules
Most technical analysis of Supernus Pharmaceuticals help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Supernus from various momentum indicators to cycle indicators. When you analyze Supernus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company was incorporated in 2005 and is headquartered in Rockville, Maryland. Supernus Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 603 people. A high-level view of Supernus Pharmaceuticals emphasizes earnings durability, balance-sheet flexibility, and competitive positioning. Current metrics include P/E of 15.25, P/B of 2.94, profit margin of -5.36%. Supernus Pharmaceuticals has market cap of 3.09 B, P/E of 15.25, ROE of -3.68%.
Methodology
Unless otherwise specified, financial data for Supernus Pharmaceuticals is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Supernus (USA Stocks:SUPN) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Information presented is compiled from public filings and market reference sources and official institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR. Updates can be delayed depending on reporting conventions. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Supernus Pharmaceuticals is covered by 6 analysts. 3 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include J.P. Morgan, Stifel, BMO Capital Markets, Oppenheimer & Co., Citigroup, RBC Capital Markets, among others. Updates may occur throughout the day.
Learn to be your own money manager
Tracking Supernus Pharmaceuticals inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Supernus Pharmaceuticals pair trading
Pair trading with Supernus Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Supernus Pharmaceuticals Pair Trading
Supernus Pharmaceuticals Pair Trading Analysis
Understanding the correlation structure around Supernus Pharmaceuticals helps portfolio managers make better tax-loss harvesting decisions. A highly correlated substitute for Supernus Pharmaceuticals ensures that the portfolio's expected return and risk profile remain largely intact through the wash-sale.
Investors use the correlation of Supernus Pharmaceuticals to identify pairs-trading opportunities. When two historically correlated assets diverge temporarily, a long/short position combining Supernus Pharmaceuticals with the diverging counterpart can generate returns with minimal net market exposure.
Correlation analysis and pair evaluation for Supernus Pharmaceuticals can support hedging context. The context can be applied within sectors, industries, or broader universes.More Resources for Supernus Stock Analysis
Reviewing Supernus Pharmaceuticals commonly begins with financial statements and performance trends. Key ratios help frame profitability, efficiency, and growth context for Supernus Pharmaceuticals Stock. Below are reports that help frame Supernus Pharmaceuticals Stock in context:Supernus Pharmaceuticals has market cap of 3.09 B, P/E of 15.25, operating margin of -28.9%. See World Market Map for portfolio-level analysis. This suggests a position in Supernus Pharmaceuticals across the allocation. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Learn how to buy and trade Supernus Stock using our step-by-step How to Buy Supernus Pharmaceuticals guide.Analysis related to Supernus Pharmaceuticals should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Quarterly Earnings Growth 0.111 | Earnings Share -0.68 | Revenue Per Share | Quarterly Revenue Growth 0.215 | Return On Assets |
Understanding Supernus Pharmaceuticals includes distinguishing between market value and book value, where book value reflects Supernus accounting equity. Supernus Pharmaceuticals' market capitalization is 3.09 B. A P/B ratio of 2.94 indicates the market values Supernus Pharmaceuticals above its accounting book value. Enterprise value stands at 2.85 B. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
The concept of value for Supernus Pharmaceuticals differs from its quoted price, since each reflects a different lens. For Supernus Pharmaceuticals, key inputs include a P/E ratio of 15.25, a P/B ratio of 2.94, a profit margin of -5.36%, ROE of -3.68%. By contrast, market price reflects the level where buyers and sellers transact.